CompletedPhase 2

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Netherlands32 participantsStarted 2007-10

Plain-language summary

The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with non-medullary thyroid carcinoma * The patients must have undergone total thyroidectomy * Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor * No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy Exclusion Criteria: * Pregnancy * Other active malignancies * Active kidney, liver or pancreatic disease or dysfunction * Unstable angina pectoris or recent (\<3 months) myocardial infarction. * Coagulopathy

What they're measuring

Proportion of patients with a favorable response to Sorafenib defined as ONE OR MORE of the following criteria: 1. Reinduction of RaI uptake by RaI scintigraphy. 2. Serum thyroglobulin levels. 3. RECIST criteria

Timeframe: 6 months

Trial details

NCT IDNCT00887107

SponsorLeiden University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Thyroid Cancer trials